IL-18BP not only reduced symptoms after exposure to 2,4-dinitrofluorobenzene (DNFB) but also significantly reduced inflammation in mice with previously untreated CHS (154); taken together, IL-18BP is a candidate for the therapeutic indication of allergic contact dermatitis and CHS. The gene discussed is IL18BP; the disease is allergic contact dermatitis.